Exelixis Inc. (EXEL) Has Broken Out To A New High On FDA Priority Review

Exelixis Inc. (EXEL) announced Monday morning that its Phase 3 trial of cabozantinib in patients with advanced hepatocellular carcinoma met its primary endpoint.

from RTT - Hot Stocks http://ift.tt/2zsRDUB
via IFTTT